# Investigating the Safety, Tolerability and Efficacy of Amorphous Calcium Carbonate (ACC) on the Treatment of Subjects With CRPC

> **NCT02864784** · PHASE1 · WITHDRAWN · sponsor: **Amorphical Ltd.**

## Conditions studied

- Castrate Resistant Prostate Cancer With Bone Metastasis

## Interventions

- **DRUG:** Amorphous calcium carbonate
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02864784
- **Lead sponsor:** Amorphical Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-06
- **Primary completion:** 2023-12
- **Final completion:** 2023-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Budget
- **Last updated:** 2024-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02864784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02864784, "Investigating the Safety, Tolerability and Efficacy of Amorphous Calcium Carbonate (ACC) on the Treatment of Subjects With CRPC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02864784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*